Concepedia

Gabriella Liszkay

GL

Statistics

Publications

51

Citations

6.8K

H-Index

27

Active since

1999

Affiliations

National Institute of Oncology(Current)

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Institut Gustave Roussy

University of Tübingen

Massachusetts General Hospital

Gabriella Liszkay is an author at National Institute of Oncology specializing in oncology, medicine, and melanoma pharmacotherapy.

ORCID

Publications per year

1999–2025

51

Publications

51

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

James Larkin, Paolo A. Ascierto, Brigitte Dréno et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

, , +16

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 1K citations · Full text

, , +11

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 586 citations

, , +11

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Paolo A. Ascierto, Michele Del Vecchio, Caroline Robert et al. · The Lancet Oncology · 2017 · 495 citations

, , +11

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto et al. · The Lancet Oncology · 2017 · 491 citations · Full text

, , +10

1–5 of 51